ArticleClinical and vaccine immunology : CVI2008
Kinetics of decline of maternal measles virus-neutralizing antibodies in sera of infants in France in 2006.
Article in Clinical and vaccine immunology : CVI, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis.BMC infectious diseases · 2020Pooled it
- Sero-epidemiological study in prediction of the risk groups for measles outbreaks in Vojvodina, Serbia.PloS one · 2019Trial
- Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Trial
- Predictors for low coverage of uptake of second dose of measles vaccine among children in sub-Saharan Africa, 2023: a systematic review and meta-analysis.Journal of pharmaceutical policy and practice · 2024Review
- Second-dose measles vaccination and associated factors among under-five children in urban areas of North Shoa Zone, Central Ethiopia, 2022.Frontiers in public health · 2022Article
- Article
- Seroprevalence of transplacentally acquired measles antibodies in HIV-exposed versus HIV-unexposed infants at six months of age.The Indian journal of medical research · 2017Article
- Decreasing Seroprevalence of Measles Antibodies after Vaccination - Possible Gap in Measles Protection in Adults in the Czech Republic.PloS one · 2017Observational
- Seroprevalences of Specific IgG Antibodies to Measles, Mumps, and Rubella in Korean Infants.Journal of Korean medical science · 2016Article
- The impact of maternal infection with Mycobacterium tuberculosis on the infant response to bacille Calmette-Guérin immunization.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Article
- Immunization of preterm infants.Human vaccines & immunotherapeutics · 2015Review
- Maternal immunization: opportunities for scientific advancement.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.Frontiers in immunology · 2014Review
- Article
- Immature CD4+CD8+ thymocytes are preferentially infected by measles virus in human thymic organ cultures.PloS one · 2012Article
- Prevalence of Maternal Measles Antibody and Its Associated Factors among Infants in Coastal Karnataka, India.Indian journal of community medicine : official publication of Indian Association of Preventive & Social MedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal age for measles vaccination is an important health issue, since maternal antibodies may neutralize the vaccine antigen before a specific immune response develops, while delaying vaccination may increase the risk of complicated diseases in infants. However, measles vaccination impacts the duration of protection afforded by transplacental transfer of maternal antibodies: vaccination-induced maternal antibodies disappear faster than disease-induced antibodies. In order to maintain protection against measles in infants, it is important to monitor the dynamics of this phenomenon in vaccinated populations. To assess the current situation in France, a multicenter, prospective seroepidemiological study was conducted in seven French hospitals between October 2005 and January 2007. Maternal measles antibody concentrations from 348 infants 0 to 15 months old were measured using the plaque reduction neutralization assay. Geometric mean concentrations and the percentage of infants with maternal measles antibody concentrations above the protection threshold (>or=120 mIU/ml) were assessed according to age. Results show that after more than 20 years of routine measles vaccination in France, maternal measles-neutralizing antibodies decrease dramatically in French infants by 6 months of age, from 1,740 mIU/ml for infants 0 to 1 month old to 223 mIU/ml for infants 5 to 6 months old, and that 90% of infants are not protected against measles after 6 months of age. Infant protection against measles could be optimized both by increasing herd immunity through an increased vaccine coverage and by lowering the age of routine vaccination from 12 to 9 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.